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Mutations of the prion protein (PrP) gene are present in patients with Gerstmann-Straussler- 
Scheinker syndrome (GSS), familial Creutzfeldt-Jakob disease (CJD), and fatal familial insomnia 
(FFI). We developed a denaturing gradient gel electrophoresis (DGGE) strategy that readily identifies 
point mutations in the PrP coding sequence. By comparison with appropriate controls, haplotypes often 
may be deduced. This method permits samples from many patients with GSS, CJD, as well as patients 
with unusual degenerative neurologic disorders, to be screened rapidly, sensitively, and inexpensively 
for the presence of known and novel PrP mutations. We illustrate the sensitivity of this approach by 
reporting 2 novel polymorphisms in the PrP coding sequence. o 1994 Wiley-Liss, Inc. 
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INTRODUCTION 
Creutzfeldt-Jakob disease (CJD) and Gerst- 
mann-Straussler-Scheinker syndrome (GSS) are 
etiologically related but phenotypically dissimilar 
neurologic disorders. GSS is characterized by 
slowly progressive ataxia, parkinsonism, and de- 
mentia beginning in the third through seventh de- 
cades and progresses to death over 2 to 10 years 
(Gerstmann et al., 1936; Masters et al., 1981). 
CJ D is characterized by rapidly progressive demen- 
tia later associated with a variety of other neuro- 
logic signs including jerking of the extremities 
(myoclonus), muscle twitching (fasciculations), 
spasticity, and blindness (Kirschbaum, 1968; Roos 
et al., 1973; Brown and Gajdusek, 1991) Neuro- 
pathologic features of these conditions include loss 
and degeneration of neurons, gliosis, spongiform 
appearance of gray matter, and variable deposition 
of extracellular amyloid (Beck and Daniel, 1987). 
These amyloid deposits contain large amounts of 
prion protein (PrP) encoded by the PrP gene on 
chromosome 20 (Kitamoto et al., 1986; Sparkes et 
al., 1986). GSS is uniformly transmitted through 
autosomal dominant inheritance (Masters et al., 
1981; Hsiao and Prusiner, 1990). In contrast, the 
majority of CJD patients have a sporadic condition 
with only 5 to 15% of CJD patients acquiring the 
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disorder through autosornal dominant inheritance 
(Brown et al., 1987; Masters et al., 1979). Iatro- 
genic CJD is transmissible through organ trans- 
plants and pharmaceutical preparations containing 
material derived from CJD or GSS patients (Duffy 
et al., 1974; Tinter ct al., 1986). There is com- 
pelling evidence that the transmissible agent or 
prion is composed largely, if not entirely, of an 
abnormal form of PrP designated PrP"' (Prusiner, 
1982, 1987). 
PrP coding sequence mutations are present in 
GSS patients and familial CJD patients (Fig. 1A) 
(Owen et al., 1989, 1992; Hsiao et al., 1989; 
Doh-ura et al., 1989; Fink et al., 1991; Nieto et 
al., 1991; Dhouhy et al., 1992; Hsiao et al., 1992; 
Goldgaber et al., 1989). These mutations are as- 
sociated specifically with these disorders and the 
rare condition, fatal familial insomnia (FFI) 
(Lugaresi et al., 1991; Medori et al., 1991). When 
tested, these mutations have shown genetic link- 
age with these disorders (Hsiao et al., 1989; 
Dhouhy et al., 1992; Speer et al., 1991; Petersen 
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FIGURE 1. (A) The locations of known point mutations of the 
PrP coding sequence are shown: coding sequence (BP 50- 
808), open box; noncoding sequence (BP 1-49), hatched 
box. (B) Amplification fragments used for DGGE analysis. 
PCR primers and reaction conditions are given in Table 1. 
(C) Melt87 analysis of PrP amplification fragments A (-.) 
and B (-). 
et al., 1992). PrP mutation at codon 10ZLe" was 
shown to be directly pathogenic when its expres- 
sion produced an inherited neurodegenerative dis- 
order in transgenic mice (Hsiao et al., 1990). 
In general, PrP mutations associated with the 
syndrome of familial CJD are different from those 
associated with GSS (Goldfarb et al., 1990). Point 
mutations in PrP codons 102LeL', 117""', 198'", 
and 21 7Arg are associated with GSS. An additional 
point mutation at codon 105LeL' was recently iden- 
tified in GSS patients with spastic paraparesis (Ki- 
tamoto et al., 1993). PrP mutations associated 
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with familial CJD include insertions of varying 
numbers of a 24-base pair repeat (144 nucleotides, 
for example) (Owen et al., 1989, 1992) between 
codons 51 and 92 and point mutations in codons 
178A’p and 20OLyS. In addition to these disease- 
specific mutations, benign PrP polymorphisms 
have been found in normal subjects, including 
point mutations in codons 124 (Hsiao et al., 1992) 
and 117 and a 24-base pair deletion (Vnencak- 
Jones et al., 1992; Laplanche et al., 1990). 
The polymorphism at PrP codon 129 may be 
clinically significant. The greatly increased fre- 
quency of homozygosity at codon 129 among spo- 
radic CJD patients (approximately 90%) compared 
to normal subjects (63%) raises the possibility that 
this codon may contribute to the development of 
developing sporadic CJD (Palmer et al., 1991). 
Furthermore, the codon 129 genotype may affect 
the age of onset of familial CJD or GSS patients 
(Baker et al., 1991; Dhouhy et al., 1992) or 
whether patients exhibit the CJD phenotype or FFI 
phenotype (Goldfarb et al., 1992). 
Observations of PrP mutations in GSS patients 
with absent or atypical (Collinge et al., 1990; 
Dhouhy et al., 1992; Hsiao et al., 1992) neuro- 
pathologic findings have raised the possibility that 
PrP-related disorders may be underrecognized. It is 
possible that some patients with inherited, degen- 
erative neurologic syndromes of undetermined eti- 
ology have PrP mutations. Comprehensive evalu- 
ation of the PrP gene in these patients requires 
more than simply screening for the presence of 
known PrP mutations. Previously, one of us (J.F.) 
used denaturing gradient gel electrophoresis 
(DGGE) (Fischer and Lerman, 1983) and allele- 
specific DNA sequencing to identify a novel PrP 
mutation (Fink et al., 1991) in a familial CJD 
patient. This approach has been extended to allow 
mutations in other regions of the PrP coding 
sequence to be detected. We show that this tech- 
nique readily identifies known PrP point muta- 
tions. In addition, this method facilitates detec- 
tion of novel PrP mutations in samples from many 
patients. We illustrate the sensitivity of this ap- 
proach by reporting two novel polymorphisms of 
the PrP coding sequence. 
MATERIALS AND METHODS 
Patients and DNA Samples 
Genomic DNA samples were obtained from 
CJD and GSS patients for whom PrP mutations 
had been identified by restriction enzyme and 
DNA sequence analysis. The exceptions were the 
normal subject for whom the codon 129v”’/129v“’, 
codon l2gMetlMet , and codon 1 29Mrt/Val genotypes 
were demonstrated by Nspl restriction enzyme 
analysis (data not shown). 
Computer Analysis 
The MELT87 computer program (generously 
provided by L. Lerman, Massachusetts Institute of 
Technology) was used to design overlapping am- 
plification fragments in which regions of the PrP 
coding sequence known to have point mutations 
(nucleotides 353 to 698) would occur in the “low- 
est melting domain.” 
PrP Amplification 
The PrP coding sequence was amplified as over- 
lapping fragments (Fig. 1B) from genomic DNA 
extracted from leukocytes. The only exceptions 
were DNA samples containing codon 1 17A’” and 
1 17v”’ for which the PrP alleles cloned into bac- 
terial plasmids served as the PCR template. PCR 
primers and amplification parameters are given in 
Table 1. Nucleotide positions are numbered ac- 
cording to Kretzschmar et  al. (1986). 
Denaturing Gradient Gel Electrophoresis 
Following amplification, PrP fragments were de- 
natured by heating to 95°C for 10 min. Reanneal- 
ing was carried out at 80°C for 2.5 min followed by 
42°C for 5 min. 5 ml of loading buffer (40% glyc- 
erol, 0.1% bromphenol blue) were added to the 50 
ml PCR product. Aliquots (20-25 pl) of this mix- 
ture were electrophoresed on denaturing gradient 
polyacrylamide gels as specified in Table 1. Mutant 
and normal PrP amplified from plasmid templates 
were mixed (1:l) prior to denaturation and rean- 
nealing in order to mimic the situation of ampli- 
fying genomic DNA from a patient who was het- 
erozygous at codon 1 1 7v”’/1 1 7A‘a. 
Restriction Enzyme Analysis 
For samples containing novel DGGE polymor- 
phisms, a portion of the prion gene (bp 361 
through 607) was amplified [5’ primer, GC- 
CAAAAACCAACATGAAGC; 3‘ primer, TG- 
GTTGTGGTGACCGTGTGC; 2 mM MgCI,; 35 
cycles of 58°C (45 sec), 72°C (1.25 min), 94°C (1 
min)]. Amplification products were electro- 
phoresed on a low-melting agarose gel and purified 
by Magic Prep columns (Promega Corp). DNA 
samples were separately digested in a total volume 
of 20 ml with 10 units of AccI and Bst71I for 2 hr 
at 37°C ( A d )  or 50°C (Bst71I). Following diges- 
tion with Bst711, proteinase K (10 mg/ml) was 
added to remove excess Bst7lI. Aliquots (10-20 
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TABLE 1. PCR Primers and Amplification Parameters 
Fragment A (Effectively scans PrP nucleotides 270 to 448) 
PCR Primers: "5A": CTGGAGGCAACCGCTACCCA (PrP nucleotides 180 + 199); "3A": TGTATGATGGGCCTGCTCAT 
(PrP nucleotides 468 + 449) 
PCR: Each 50 ml reaction contains 1 mg template DNA, 200 mM each dNTP, 0.25 unit Taq polymerase, 0.66 mg of each 
primer, 2 mM MgCI,; 94T, 1.0 min; 60°C. 0.5 min; 72"C, 1.25 min; 35 cycles 
DGGE: Stacking gel: 6% polyacrylamide gel with 2 9 1  crosslinker; gradient gel: 9% polyacrylamide gel with 22:l crosslinker; 
gradient of 50 to 75% denaturant (100% denaturant = 40% formamidei7 M urea); buffer: 40 mM Tris-acetate/l mM EDTA, 
pH 7.8; electrophorese at 14 mA, 65"C, for 18 hr 
ml) of each sample were electrophoresed on 1.6% 
agarose gels. 
RESULTS 
We used the MELTS7 computer program (Ler- 
man 1990) (Fig. 1C) to design a strategy in which 
regions of the PrP coding sequence known to have 
point mutations would be in the lowest melting 
domain of an amplification fragment. Figure 2A 
and B show that known PrP point mutations are 
readily detectable by DGGE. 
The sensitivity of this approach suggested that 
novel mutations in these regions would be readily 
detected. This prediction was confirmed by finding 
unique DGGE polymorphisms in a control subject 
and in a patient with Alzheimer's disease (AD) 
(Fig. 3A). The control subject was a male who 
died at age 69 and had no evidence of AD or 
spongiform degeneration at postmortem examina- 
tion. Direct DNA sequencing revealed substitu- 
tion of guanine (for adenine) at nucleotide 561 in 
the control subject. This polymorphism creates a 
Bst71I site (Fig. 3B) and predicts substitution of 
serine for asparagine at codon 171 (AAC -+ 
AGC). Whether the codon 171'" -+ Asp is a rare 
but benign variant or potentially pathogenic is not 
known. Direct DNA sequencing of the AD pa- 
tient's sample revealed substitution of adenine for 
guanine at nucleotide 532. This polymorphism 
creates an AccI site, deletes an RsaI site (Fig. 3B), 
and does not change the valine at codon 161 
(GTG -+ GTA). 
In addition to detecting known and novel PrP 
mutations, when used in conjunction with restric- 
tion enzyme analysis, our method often can deter- 
mine PrP haplotypes. Determination of PrP hap- 
lotypes by DGGE is particularly useful in cases 
where the mutation either does not change a re- 
Fragment B (Effectively scans PrP nucleotides 440 to 787) 
PCR Primers: "5": (sequence given above) "3B': CCTTCCTCATCCCACTATCAGGAAGATGAG (PrP nucleotides 817 + 
PCR: Reaction conditions are the same as for fragment A; 94°C. 1.0 rnin; 60"C, 0.75 min; 72"C, 1.5 min; 35 cycles 
DGGE Stacking gel: 5% polyacrylamide gel with 29:l crosslinker; gradient gel: 5% polyacrylamide gel with 29:l crosslinker; 
gradient of 40 to 75% denaturant (100% denaturant = 40% formamide/7 M urea); buffer as above; electrophorese at 28 
mA, 60"C, for 16 hr 
788) 
- 
striction site or when the location of the novel 
restriction site makes it difficult to detect the re- 
sulting RFLP (such as in the case of codon 129 and 
124 polymorphisms). Lanes 1, 2, 4, and 5 in Figure 
2A illustrate how haplotypes may be deduced and 
the effects of mutations on the relative location of 
homoduplexes. Consider as controls samples in 
Figure 2A, lanes 1 and 2 amplified from normal 
subjects who were homozygous at codon 12gMetIMet 
(lane 1 ) and homozygous at codon I 29Va"Va' (lane 
2). Lane 4 contains PrP amplified from a normal 
subject heterozygous for a benign, single nucle- 
otide change at codon 117A'a -+ Ala (GCA -+ 
GCG). Previously, digesting this patient's sample 
with NspI indicated that the subject was heterozy- 
gous at codon 129Met/V"' . The upper homoduplex 
has the same mobility as the normal subject with 
codon 1 29Met'Mrt (lane 1 ), indicating that the sub- 
ject's normal allele (1 17""A) encodes 129Met. 
Knowing that the subject is heterozygous at both 
codons 117(GCA -+ GCG) and 129Met/Val indi- 
cates that the other allele must encode 117"CG 
and 129Met. The haplotypes are deduced to be 
11 7w'L1' TYrL (GCA), 1 29Met/1 1 7VAR'ANT (GCG), 
129""'. The lower (mutant) homoduplex focuses 
slightly below that of the normal 129""'-contain- 
ing homoduplex in lane 2 owing to the slightly 
increased melting temperature conferred by the A 
to G nucleotide substitution. This illustrates the 
correlation between the nature of the polymor- 
phism and the relative location of the mutant ho- 
moduplex. G (or C) to A (or T )  changes decrease 
the melting temperature of the mutant homodu- 
plex causing it to focus earlier (higher) in the gel. 
The converse is true regarding A (or T) to G (or 
C) changes. Lane 5 (Fig. 2A) contains material 
from a GSS patient with a pathogenic double mu- 
. Like the tation at codon 11 7"CA - GTG (Ah  - Val) 
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FIGURE 2. Demonstration of PrP point mutations by DGGE 
analysis. (A) DGGE of PrP Fragment A amplified from a 
normal subjuct homozygous at codon 129Me'Met (lane 1); a 
normal subject homozygous at  codon 129va"va' (lane 2); a 
GSS patient heterozygous for a pathogenic mutation at 
codon 102Leu'Pro and a polymorphism at codon 129va1'va1 
(lane 3); a normal subject with a benign, single-nucleotide 
change at codon 117GCA-GCG and heterozygosity at codon 
129Met/Val (lane 4); a CJD patient heterozygous for a patho- 
genic, double nucleotide mutation at codon 1 17GCA'GTG 
(Ala-Val) and heterozygous for a benign polymorphism at 
codon 129Met'Va' (lane 5); a normal subject heterozygous for 
a benign polymorphism at codon 129Md'Va' (lane 6); a nor- 
mal subject with a 24 base pair deletion who was also het- 
sample in lane 4, this subject also has the patho- 
genic codon 11 7"CA mutation on the same allele 
containing the benign change at codon 129vd'. In 
contrast to the downward displacement of 
I 17GC", 129v"' (compared with 1 17CITA, 129v"'), 
the double nucleotide substitution causes negligi- 
ble displacement of the homoduplex since the two 
substitutions have opposing affects on melting 
temperature (C -+ T and A -+ G). Note, how- 
ever, the separation of homoduplexes from hetero- 
duplexes. Compared to homoduplexes, the hetero- 
duplexes have greatly reduced melting temperature 
because of the 2-base pair mismatch that forms 
erozygous at codon 129v"1'"a1 (lane 7); a normal subject with 
a 24 base pair deletion who was homozygous at codon 
12gMet'Met (lane 8). (B) DGGE of PrP Fragment B amplified 
from a normal subject homozygous at codon 129Met'Met (lane 
1); a normal subject homozygous at codon 129Va1'Val (lane 2); 
a familial CJD patient heterozygous at codon 178A'p'A"" who 
was homozygous at codon 129v"1'va1 (lane 3); a familial CJD 
patient who was heterozygous at codon 178A"p'A'" and 
heterozygous at codon 129M"'Va1 (lane 4); a GSS patient 
heterozygous at codon 198Ph"Ser and homozygous at 
codon 129va"va' (lane 5); a CJD patient heterozygous 
at codon 200G1u'Ly" (lane 6); a GSS patient heterozygous at 
codon 217Gl"'A'g and heterozygous at codon 129Me"Va' 
(lane 7). 
when these mutant and normal alleles reanneal 
(Fig. 2A, lanes 4 and 5). 
As expected, the largest separation of homo- 
and heteroduplexes occurred in samples with the 
24-base pair deletion (Fig. 2A, lanes 8 and 9). 
Since this deletion occurs in the octapeptide re- 
peat region, heteroduplexes may form in 2 ways. 
The deletion creates a 24-base pair mismatch that 
may be placed either internally (creating a 24-base 
pair loop) or at the 5' end (creating staggered ends 
and a terminal region of nonhomology). Owing to 
slight variations in this repeat region, however, 
this latter structure creates 3 separate single-nucle- 
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FIGURE 3. Detection of novel PrP point mutations. (A) DGGE 
detection of novel polymorphisms in PrP coding sequence. 
Control samples in lanes 1 and 2 are PrP (fragment B) am- 
plified from a normal subject homozygous at codon 129M"' 
Met (lane 1) and a familial CJD patient heterozygous for a 
benign polymorphism at codon 129Ma'Va1 and heterozygous 
for a pathogenic mutation at codon 178ASp'As" (lane 2). Sam- 
ples with novel DGGE polymorphisms (lanes 3 and 4) are 
from an Alzheimer's patient homozygous at codon 129M"'Me' 
and heterozygous for a benign nucleotide polymorphism at 
codon 161GTGGTA (Val-Val) (lane 3); and a control subject 
homozygous at codon 129va"va1 and heterozygous at codon 
otide mismatches (at nucleotides 277, 295, and 
301). We feel that this latter heteroduplex with 
staggered 5 ' ends and 3 separate single-nucleotide 
mismatches best explains the large difference in 
melting profiles (and resulting gel separation) be- 
tween hetero- and homoduplex species with the 
24-base pair deletion. 
DISCUSSION 
DGGE is an extremely sensitive and efficient 
method for screening large numbers of samples for 
single nucleotide substitutions, small insertions, 
and deletions. Principles of mutation detection by 
DGGE are reviewed elsewhere (Meyers et al., 
1987). 
Known PrP point mutations (reviewed in 
Palmer and Collinge, 1993) occur between nucle- 
otides 353 and 698, and are clearly evident in our 
PrP amplification fragments. We have found two 
(lane 4). (B) Restriction enzyme anal- 
ysis of PrP amplification fragment B confirms the presence of 
novel polymorphisms. PrP amplified from control subject 
(Ctrl) (lanes 1 and 2) and Alzheimer's patient (AD) with 
codon 161 polymorphism (lanes 3 and 4) prior to ( - )  and 
following ( + ) digestion with AccI illustrate the creation of a 
novel AccI site in the AD patient (lane 4). PrP amplified from 
control subject (Ctrl) (lanes 6 and 7) and subject (Pt) with 
codon 171 polymorphism (lanes 8 and 9) prior to (-) and 
following ( + ) digestion with Bst71I illustrate the creation of 
a novel Bst711 site in the lane 9. Lane 5 contains molecular 
weight (MW) marker (123 bp ladder). 
171AAC-AGC ( A s ~ S e r )  
novel PrP point mutations using our method. This 
experience predicts that DGGE analysis of PrP 
fragments A and B can identify other, currently 
unknown mutations in the region of the PrP gene 
between nucleotides 270 and 787. With the use of 
an alternate 3' primer for fragment B (5' + 3': 
GTGAAAACAGGAAGACCTTCC) , it should 
be possible to extend the "scannable" region to 
include the remaining 19 base pairs in the 3' end. 
There are no known point mutations in nucle- 
otides 1 through 270 of the PrP coding sequence 
(the first 49 nucleotides of which are not trans- 
lated). All known polymorphisms in this region 
are either insertions of varying numbers of 24 nu- 
cleotide repeats or a 24-base pair deletion and are 
readily detectable by PCR and conventional gel 
electrophoresis. Alternatively, temperature gradi- 
ent gel electrophoresis (TGGE) (Riesner et al., 
1992) or single-strand conformation analysis 
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(Orita et al., 1989) may be useful to analyze this 
region. 
It is possible that there are additional PrP mu- 
tations, particularly in familial CJD patients. It is 
not known whether familial CJD patients who 
lacked PrP codon 102Le1' or 2OOLYs mutations 
(Goldgaber et al., 1989) had other PrP mutations 
(such as codon 178Asn, for instance) or entirely 
normal PrP coding sequences. Finding PrP mu- 
tations in such patients would confirm the diagno- 
sis and help provide genetic counseling for rela- 
tives at risk. The absence of PrP mutations in such 
patients would raise the possibility that these pa- 
tients with clinical and pathologic features similar 
to familial CJD had genetically unrelated disorders 
or that PrP involvement might be related to ab- 
normal amounts of PrP (due to increased rates of 
transcription, translation, increased mRNA stabil- 
ity, or reduced PrP catabolism, for instance), or 
even aberrant posttranslational modification of 
PrP. 
A PrP insertional mutation was found in a pa- 
tient with familial ataxia and dementia character- 
istic of GSS in whom there was no evidence of 
spongiform degeneration (Collinge et al., 1990; 
Poulter et al., 1992). Amyloid deposits in this pa- 
tient were evident only with immunohistochemi- 
cal staining (Poulter et al., 1992). Furthermore, 
mutations in PrP codons 198'" and 217A'g were 
present in patients with dominantly inherited de- 
mentia, ataxia, and parkinsonism whose postmor- 
tem findings of senile plaques and neurofibrillary 
tangles were similar in appearance (but not distri- 
bution) to Alzheimer's disease in contrast to 
spongiform degeneration characteristic of GSS and 
CJD (Dhouhy et al., 1992; Hsiao et al., 1992). 
Using the parameters of disease transmissibility 
(Brown et al., 1993) and immunologic detection 
of PrP (Brown et al., 1993; Kitamoto et al., 1992), 
Brown ( 1993) conclude that transmissible spongi- 
form encephalopathies are quite rare and not likely 
to be misdiagnosed as other neurodegenerative dis- 
orders. Nonetheless, we should consider the pos- 
sibility that all disorders related to prion gene mu- 
tations may not exhibit a uniformly high rate of 
disease transmission to laboratory animals or a uni- 
form neuropathologic pattern. The first category of 
patients to be examined for novel PrP mutations 
include familial CJD patients lacking known PrP 
mutations as well as some patients diagnosed as 
early-onset Alzheimer's disease. Some early-onset 
familial AD patients, and particularly those with 
cortical Lewy bodies, have clinical and pathologic 
features similar to CJD including onset of symp- 
toms in the third or fourth decade, subacute pro- 
gressive dementia, myoclonus, and spongiform de- 
generation (Feldman et al., 1963; Hansen et  al., 
1990). Although previous efforts have failed to de- 
tect PrP insertional mutations and point mutations 
at codons 102Lek', 1 17Va', and 20OLYs in AD pa- 
tients (Schellenburg et al., 1991), the possibility 
of novel PrP mutations in patients with atypical 
dementia has not been systematically evaluated. 
The DGGE approach allows investigators to rap- 
idly determine whether PrP mutations are present 
in seemingly unrelated neurodegenerative disor- 
ders, including progressive subcortical gliosis, pro- 
gressive myoclonic epilepsy, olivopontocerebellar 
atrophy, multisystem atrophy, progressive supranu- 
clear palsy, and spinocerebellar degenerations. 
Familial CJD and GSS seem to be useful models 
for more common inherited neurodegenerative dis- 
orders. Elucidating the central role of abnormal 
PrP in GSS and familial CJD and creating an an- 
imal model of GSS have advanced our knowledge 
of mechanisms by which mutations can cause in- 
herited brain disease. Defining the nature and ex- 
tent of additional PrP mutations in patients with 
disparate neurologic conditions will provide fur- 
ther insight into the basis for regionally specific 
neuronal degeneration in these conditions. Unrav- 
eling this pathophysiologic cascade may give some 
insight into potential mechanisms underlying the 
more prevalent degenerative neurologic disorders 
of unknown etiology. 
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